<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TICAGRELOR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TICAGRELOR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 180 mg for 1 dose, then 90 mg twice daily usually for up to 12 months.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Alternative to clopidogrel in patients undergoing percutaneous coronary intervention</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                180 mg.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in moderate or severe impairment&#8212;no information available.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active bleeding</li>
            <li>history of intracranial haemorrhage</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Bruising, dyspnoea, haemorrhage,
              </p>
              <p>
                <strong>uncommon:</strong> Abdominal pain, diarrhoea, dizziness, dyspepsia, gastritis, headache, nausea, pruritus, rash, vomiting,
              </p>
              <p>
                <strong>rare:</strong> Confusion, constipation, hyperuricaemia, paraesthesia, raised serum creatinine, vertigo,
              </p>
        
        
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA236</h3>
              <p outputclass="title">Ticagrelor for the treatment of acute coronary syndromes (October 2011)</p> <p>Ticagrelor, in combination with low-dose aspirin, is recommended for up to 12 months as a treatment option in adults with acute coronary syndromes, that is, people:</p> <ul> <li>with ST-segment elevation myocardial infarction&#8212;defined as ST elevation or new left bundle branch block on electrocardiogram&#8212;that cardiologists intend to treat with primary percutaneous coronary intervention, <b>or</b> </li> <li>with non-ST-segment elevation myocardial infarction (NSTEMI), <b>or</b> </li> <li>admitted to hospital with unstable angina&#8212;defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the characteristics defined below. Before ticagrelor is continued beyond the initial treatment, the diagnosis of unstable angina should first be confirmed, ideally by a cardiologist. Characteristics to be used in defining treatment with ticagrelor for unstable angina are:<ul> <li>age 60 years or older;</li> <li>previous myocardial infarction or previous coronary artery bypass grafting;</li> <li>coronary artery disease with stenosis of 50% or more in at least two vessels;</li> <li>previous ischaemic stroke;</li> <li>previous transient ischaemic attack, carotid stenosis of at least 50%, or cerebral revascularisation;</li> <li>diabetes mellitus;</li> <li>peripheral arterial disease, <b>or</b> </li> <li>chronic renal dysfunction (creatinine clearance less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>).</li> </ul> </li> </ul><xref format="html" href="http://www.nice.org.uk/TA236">www.nice.org.uk/TA236</xref>
                <a href="http://www.nice.org.uk/TA236" target="_blank">www.nice.org.uk/TA236</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Asthma
          </li>
          <li>
            bradycardia (unless pacemaker fitted)
          </li>
          <li>
            chronic obstructive pulmonary disease
          </li>
          <li>
            discontinue 7 days before elective surgery if antiplatelet effect not desirable
          </li>
          <li>
            history of hyperuricaemia
          </li>
          <li>
            patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or coagulation disorders)
          </li>
          <li>
            second- or third-degree AV block (unless pacemaker fitted)
          </li>
          <li>
            sick sinus syndrome (unless pacemaker fitted)
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor renal function 1 month after initiation.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TICAGRELOR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77087"><a href="../medicinalForm/PHP77087.html" data-target="#PHP77087" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
